RS52197B - Kalijumova so inhibitora hiv integraze - Google Patents

Kalijumova so inhibitora hiv integraze

Info

Publication number
RS52197B
RS52197B RS20120021A RSP20120021A RS52197B RS 52197 B RS52197 B RS 52197B RS 20120021 A RS20120021 A RS 20120021A RS P20120021 A RSP20120021 A RS P20120021A RS 52197 B RS52197 B RS 52197B
Authority
RS
Serbia
Prior art keywords
compound
salt
solution
crystalline
potassium
Prior art date
Application number
RS20120021A
Other languages
English (en)
Serbian (sr)
Inventor
Philip Jones
Kevin M. Belyk
Henry G. Morrison
Vincenzo Summa
Original Assignee
Merck Sharp & Dohme Corp.
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36171569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52197(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp., Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. filed Critical Merck Sharp & Dohme Corp.
Publication of RS52197B publication Critical patent/RS52197B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20120021A 2004-12-03 2005-12-02 Kalijumova so inhibitora hiv integraze RS52197B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63313204P 2004-12-03 2004-12-03
PCT/US2005/043728 WO2006060712A2 (en) 2004-12-03 2005-12-02 Potassium salt of an hiv integrase inhibitor

Publications (1)

Publication Number Publication Date
RS52197B true RS52197B (sr) 2012-10-31

Family

ID=36171569

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120021A RS52197B (sr) 2004-12-03 2005-12-02 Kalijumova so inhibitora hiv integraze

Country Status (35)

Country Link
US (2) US7754731B2 (OSRAM)
EP (2) EP1819683B1 (OSRAM)
JP (1) JP4705956B2 (OSRAM)
KR (2) KR20130122031A (OSRAM)
CN (1) CN101068793B (OSRAM)
AR (2) AR052034A1 (OSRAM)
AT (2) ATE534645T1 (OSRAM)
AU (1) AU2005311671B8 (OSRAM)
BR (1) BRPI0518760A8 (OSRAM)
CA (1) CA2588398C (OSRAM)
CR (1) CR9146A (OSRAM)
CY (1) CY1112859T1 (OSRAM)
DK (1) DK1819700T3 (OSRAM)
EA (1) EA012418B1 (OSRAM)
ES (2) ES2375788T3 (OSRAM)
GE (1) GEP20105086B (OSRAM)
HR (1) HRP20120066T1 (OSRAM)
IL (1) IL183614A (OSRAM)
MA (1) MA29120B1 (OSRAM)
ME (1) ME01985B (OSRAM)
MX (1) MX2007006639A (OSRAM)
MY (1) MY144320A (OSRAM)
NI (1) NI200700138A (OSRAM)
NO (1) NO338784B1 (OSRAM)
NZ (1) NZ555376A (OSRAM)
PE (1) PE20061148A1 (OSRAM)
PL (1) PL1819700T3 (OSRAM)
PT (1) PT1819700E (OSRAM)
RS (1) RS52197B (OSRAM)
SI (1) SI1819700T1 (OSRAM)
TN (1) TNSN07215A1 (OSRAM)
TW (1) TWI344463B (OSRAM)
UA (1) UA87884C2 (OSRAM)
WO (2) WO2006060730A2 (OSRAM)
ZA (1) ZA200704130B (OSRAM)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1725528B1 (en) 2004-03-11 2013-05-29 4Sc Ag Sulphonylpyrroles as hdac inhibitors
KR20070085702A (ko) * 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도
CA2588465C (en) * 2004-12-03 2013-10-01 Merck & Co., Inc. Pharmaceutical composition containing an anti-nucleating agent
KR101351059B1 (ko) * 2004-12-03 2014-02-17 머크 샤프 앤드 돔 코포레이션 방출 속도 조절용 조성물을 포함하는 카복스아미드 ｈｉｖ 인테그라제 억제제의 약제학적 제형
KR20080110807A (ko) * 2006-03-14 2008-12-19 머크 앤드 캄파니 인코포레이티드 마이크로 분쇄 및 마이크로-시드상의 결정화에 의한 결정성유기 미세입자 조성물의 생성 방법과 장치 및 이의 용도
US7888375B2 (en) 2006-07-19 2011-02-15 The University Of Georgia Research Foundation, Inc Pyridinone diketo acids: inhibitors of HIV replication
WO2009009531A2 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives for the treatment of hiv infections
AU2008346833B2 (en) * 2008-01-08 2014-07-17 Merck Sharp & Dohme Corp. Process for preparing N-substituted hydroxypyrimidinone carboxamides
ES2549387T3 (es) 2009-06-02 2015-10-27 Hetero Research Foundation Procedimiento de preparación de raltegravir potásico amorfo
WO2011024192A2 (en) 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
CA2777937C (en) 2009-10-26 2017-08-29 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
DE102009056636A1 (de) 2009-12-02 2011-06-09 Ratiopharm Gmbh Raltegravir-Polymorphe
WO2011071849A2 (en) * 2009-12-07 2011-06-16 University Of Georgia Research Foundation, Inc. Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications
ES2362598B1 (es) * 2009-12-17 2012-06-13 Consejo Superior De Investigaciones Científicas (Csic) Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus.
RU2012146517A (ru) * 2010-04-01 2014-05-10 Тева Фармасьютикал Индастриз Лтд. Соли ральтегравира и их кристаллические формы
CA2794952C (en) * 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2011148381A1 (en) * 2010-05-25 2011-12-01 Hetero Research Foundation Salts of raltegravir
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
CN101914067B (zh) * 2010-08-26 2012-07-11 陈岱岭 N-甲基嘧啶酮的合成方法
JO3209B1 (ar) * 2010-11-05 2018-03-08 H Lundbeck As طريقة لتصنيع نالتريكسون
WO2012103105A1 (en) 2011-01-24 2012-08-02 Assia Chemical Industries Ltd. Processes for preparing raltegravir and intermediates in the processes
WO2012106534A2 (en) * 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
US9163009B2 (en) 2011-04-06 2015-10-20 Lupin Limited Salts of raltegravir
CA2833006A1 (en) * 2011-04-22 2012-10-26 Merck Sharp & Dohme Corp. Taste-masked formulations of raltegravir
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2522665A1 (en) 2011-05-03 2012-11-14 Sandoz Ag Crystalline sodium salt of an HIV integrase inhibitor
EP2529741B1 (en) 2011-06-01 2014-02-12 Ratiopharm GmbH Composition and Tablet Comprising Raltegravir
WO2013037731A1 (de) 2011-09-16 2013-03-21 Hexal Ag Neue polymorphe form von raltegravir-kalium
CN103130788B (zh) * 2011-11-24 2015-09-02 南开大学 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CN103130787B (zh) * 2011-11-24 2015-06-10 南开大学 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
US9403809B2 (en) 2011-12-26 2016-08-02 Emcure Pharmaceuticals Limited Synthesis of raltegravir
EP2806857A1 (en) 2012-01-25 2014-12-03 Lupin Limited Stable amorphous raltegravir potassium premix and process for the preparation thereof
WO2014064711A2 (en) * 2012-10-22 2014-05-01 Hetero Research Foundation Methods of administering raltegravir and raltegravir compositions
EP2818470A1 (en) 2013-06-27 2014-12-31 Basf Se Cocrystals of raltegravir potassium
EP3022209B1 (en) * 2013-07-17 2018-03-07 ratiopharm GmbH Dolutegravir potassium salt
ES2713686T3 (es) 2014-02-03 2019-05-23 Mylan Laboratories Ltd Procedimiento para la preparación de intermedios de Raltegravir
EP3119773A1 (en) 2014-03-21 2017-01-25 Mylan Laboratories Ltd. A premix of crystalline raltegravir potassium salt and a process for the preparation thereof
US10257840B2 (en) 2014-10-22 2019-04-09 Telefonaktiebolaget Lm Ericsson (Publ) Operation of wireless local area network in the presence of periodic interference
WO2016075605A1 (en) 2014-11-10 2016-05-19 Aurobindo Pharma Ltd An improved process for the preparation of raltegravir
EP3472134B1 (en) 2016-06-21 2021-10-20 Pharmathen S.A. Process for preparing compounds useful as intermediates for the preparation of raltegravir
WO2018051239A1 (en) 2016-09-15 2018-03-22 Lupin Limited Process for the preparation of pure and stable crystalline raltegravir potassium form 3
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
CA3080012A1 (en) 2017-11-14 2019-05-23 Cambrex Profarmaco Milano S.R.L. Process for the preparation of raltegravir
WO2019236395A1 (en) * 2018-06-06 2019-12-12 Merck Sharp & Dohme Corp. Formulations of raltegravir
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
EP4093380A1 (en) 2020-01-23 2022-11-30 Lupin Limited Pharmaceutical compositions of raltegravir

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624391A5 (OSRAM) * 1976-12-14 1981-07-31 Ciba Geigy Ag
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5717097A (en) 1991-11-08 1998-02-10 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL121789A (en) * 1996-10-03 2001-06-14 Rohm & Haas A medicinal product for inhibiting mammalian cell tumors
HK1042701A1 (zh) 1998-12-25 2002-08-23 盐野义制药株式会社 具有hiv整合酶抑制活性的芳族杂环化合物
IT1318424B1 (it) 2000-03-24 2003-08-25 Unihart Corp Composti con attivita' anti-hiv.
ATE430745T1 (de) 2000-10-12 2009-05-15 Merck & Co Inc Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
DE122008000016I1 (de) 2001-10-26 2011-12-01 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamidhemmerder HIV-integrase.
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CN102153540A (zh) 2001-12-21 2011-08-17 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物
SI1564210T1 (sl) 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
CN100343253C (zh) 2002-12-27 2007-10-17 P·安杰莱蒂分子生物学研究所 用作HIV整合酶抑制剂的四氢－4H－吡啶并[1,2－а]嘧啶和相关化合物
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
KR20070085702A (ko) 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도
CA2588465C (en) 2004-12-03 2013-10-01 Merck & Co., Inc. Pharmaceutical composition containing an anti-nucleating agent
KR101351059B1 (ko) * 2004-12-03 2014-02-17 머크 샤프 앤드 돔 코포레이션 방출 속도 조절용 조성물을 포함하는 카복스아미드 ｈｉｖ 인테그라제 억제제의 약제학적 제형

Also Published As

Publication number Publication date
KR101350420B1 (ko) 2014-02-17
AR052034A1 (es) 2007-02-28
TWI344463B (en) 2011-07-01
UA87884C2 (uk) 2009-08-25
KR20070089990A (ko) 2007-09-04
WO2006060712A3 (en) 2006-09-21
JP4705956B2 (ja) 2011-06-22
JP2008521933A (ja) 2008-06-26
EA012418B1 (ru) 2009-10-30
HRP20120066T1 (hr) 2012-03-31
NO20073404L (no) 2007-07-02
AU2005311671A1 (en) 2006-06-08
AU2005311671B8 (en) 2011-02-10
MA29120B1 (fr) 2007-12-03
WO2006060730A2 (en) 2006-06-08
CA2588398C (en) 2011-07-12
TNSN07215A1 (en) 2008-11-21
KR20130122031A (ko) 2013-11-06
ES2370136T3 (es) 2011-12-13
GEP20105086B (en) 2010-10-11
MX2007006639A (es) 2007-06-19
IL183614A0 (en) 2007-09-20
ES2375788T3 (es) 2012-03-06
BRPI0518760A2 (pt) 2008-12-09
US20100249410A1 (en) 2010-09-30
AU2005311671B2 (en) 2011-01-27
EP1819700B1 (en) 2011-11-23
BRPI0518760A8 (pt) 2017-12-12
ZA200704130B (en) 2008-08-27
IL183614A (en) 2012-03-29
PL1819700T3 (pl) 2012-04-30
AR101429A2 (es) 2016-12-21
CY1112859T1 (el) 2016-04-13
NZ555376A (en) 2009-11-27
DK1819700T3 (da) 2012-03-19
ATE534645T1 (de) 2011-12-15
NO338784B1 (no) 2016-10-17
EP1819683A2 (en) 2007-08-22
TW200631944A (en) 2006-09-16
CN101068793B (zh) 2011-05-25
EP1819700A2 (en) 2007-08-22
ATE518844T1 (de) 2011-08-15
PE20061148A1 (es) 2006-11-09
MY144320A (en) 2011-08-29
WO2006060712A2 (en) 2006-06-08
WO2006060712A9 (en) 2006-07-27
NI200700138A (es) 2008-05-13
PT1819700E (pt) 2012-02-01
CR9146A (es) 2007-10-04
US8357798B2 (en) 2013-01-22
SI1819700T1 (sl) 2012-07-31
US20060122205A1 (en) 2006-06-08
EA200701204A1 (ru) 2007-12-28
ME01985B (me) 2012-10-31
US7754731B2 (en) 2010-07-13
CN101068793A (zh) 2007-11-07
EP1819683B1 (en) 2011-08-03
WO2006060730A3 (en) 2006-08-17
CA2588398A1 (en) 2006-06-08
HK1115011A1 (en) 2008-11-14

Similar Documents

Publication Publication Date Title
RS52197B (sr) Kalijumova so inhibitora hiv integraze
JP2018115191A (ja) ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形
US12435026B2 (en) Solabegron zwitterion and uses thereof
EP4114527A1 (en) Inhibitors of human immunodeficiency virus replication
IL297041A (en) Inhibitors of human immunodeficiency virus replication
EP1904067B1 (en) Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
US8771733B2 (en) Pharmaceutical composition containing an anti-nucleating agent
JP6275644B2 (ja) Ｎ−［２−（｛２−［（２Ｓ）−２−シアノピロリジン−１−イル］−２−オキソエチル｝アミノ）−２−メチルプロピル］−２−メチルピラゾロ［１，５−ａ］ピリミジン−６−カルボキサミドの結晶
KR20070054208A (ko) 아자비사이클로헥산의 신규한 다형체
KR20250149691A (ko) 항섬유화 화합물의 고체 형태, 염 및 다형체
ES3035604T3 (en) Forms and compositions of inhibitors of plasma kallikrein
JP2005501857A (ja) Ｈｉｖインテグラーゼ阻害剤のナトリウム塩
EP1275386A1 (en) Solid dispersion with improved absorbability
WO2016147206A1 (en) Process for the preparation of amorphous idelalisib and its premix
US20250019370A1 (en) L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof
WO2020072870A1 (en) Co-crystal forms of baricitinib
HK1115011B (en) Potassium salt of an hiv integrase inhibitor
US20130261134A1 (en) Mesylate salt forms of a potent hcv inhibitor
CN108341841B (zh) 一种替诺福韦艾拉酚胺与门冬氨酸的盐
HK40018109A (en) Tenofovir alafenamide hemifumarate